RCAG
RDHL

Rehmann Capital Advisory Group’s Redhill Biopharma RDHL Stock Holding History

Rehmann Capital Advisory Group’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-25
Closed -$3.51K – 567
2022
Q4 		$3.51K Hold
25
– – ﹤0.01% 556
2022
Q3 		$12.6K Buy
+25
New +$21.8K ﹤0.01% 527

Other funds holding RDHL

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Rehmann Capital Advisory Group's RDHL Position: Q1 2023 in Review

Rehmann Capital Advisory Group sold out of Redhill Biopharma (RDHL) in Q1 2023, closing a stake of 25 shares — an estimated $3.51K sold.

Rehmann Capital Advisory Group first reported a position in RDHL in Q3 2022 and held it in 2 quarters. The position peaked at $12.6K in Q3 2022. 16 funds tracked by Wall St. Rank hold RDHL as of Q1 2023.

  • Rehmann Capital Advisory Group reported no remaining Redhill Biopharma position as of Q1 2023 after selling out during the quarter.
  • Rehmann Capital Advisory Group sold 25 Redhill Biopharma shares in Q1 2023, an estimated $3.51K.
  • Rehmann Capital Advisory Group first reported a position in Redhill Biopharma in Q3 2022 and held it in 2 quarters.
  • Rehmann Capital Advisory Group's Redhill Biopharma position peaked at $12.6K in Q3 2022.
  • 16 funds tracked by Wall St. Rank held Redhill Biopharma as of Q1 2023.

Based on Rehmann Capital Advisory Group's 13F filing for Q1 2023, filed 12 May 2023.